title: Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
authors.forename: Ioannnis
authors.initials: I
authors.lastname: Mitroulis
authors.forename: Chrisoula
authors.initials: C
authors.lastname: Hatzara
authors.forename: Anna
authors.initials: A
authors.lastname: Kandili
authors.forename: Emilia
authors.initials: E
authors.lastname: Hadziyannis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Vassilopoulos
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006509:Hepatitis B / Q000150:complications*; D006510:Hepatitis B Antibodies / Q000032:analysis / Q000097:blood; D006515:Hepatitis B virus / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000150:complications* / Q000188:drug therapy*; D000069283:Rituximab; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D006510:Hepatitis B Antibodies; D000069283:Rituximab